Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients with Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Recurrent Lung Non-Small Cell Carcinoma
Stage II Lung Cancer AJCC V8
Stage III Lung Cancer AJCC V8
Unresectable Lung Non-Small Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide
Drug: Paclitaxel
Drug: Pemetrexed
Radiation: Proton Beam Radiation Therapy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2017-04-28

Last Posted Date: 2024-12-16

Lead Sponsor: Mayo Clinic

Target Recruit Count: 18

Registration Number: NCT03132532

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma

Phase 2

Recruiting

Conditions: Peritoneal Carcinomatosis
Adrenocortical Carcinoma

Interventions: Drug: Cisplatin
Drug: Sodium thiosulfate
Procedure: Cytoreductive surgery

First Posted Date: 2017-04-25

Last Posted Date: 2023-09-13

Lead Sponsor: Columbia University

Target Recruit Count: 30

Registration Number: NCT03127774

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Phase 3

Active, not recruiting

Conditions: Ganglioneuroblastoma
Neuroblastoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Drug: Carboplatin
Drug: Busulfan
Drug: Cisplatin
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Dexrazoxane Hydrochloride
Biological: Dinutuximab
Drug: Doxorubicin Hydrochloride
Procedure: Echocardiography
Drug: Etoposide Phosphate
Radiation: External Beam Radiation Therapy
Radiation: Iobenguane I-123
Drug: Isotretinoin
Radiation: Iobenguane I-131
Procedure: Multigated Acquisition Scan
Drug: Lorlatinib
Drug: Melphalan Hydrochloride
Procedure: Positron Emission Tomography
Procedure: Magnetic Resonance Imaging
Biological: Sargramostim
Procedure: Therapeutic Conventional Surgery
Drug: Thiotepa
Drug: Topotecan Hydrochloride
Drug: Vincristine Sulfate

First Posted Date: 2017-04-25

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 724

Registration Number: NCT03126916

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States

and more 158 locations

Endostar First-line Treatment of Advanced NSCLC

Phase 2

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Endostar
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2017-04-21

Last Posted Date: 2017-04-21

Lead Sponsor: China Medical University, China

Target Recruit Count: 150

Registration Number: NCT03123445

Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)

Phase 1

Terminated

Conditions: Small Cell Lung Cancer

Interventions: Drug: M3814
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2017-04-17

Last Posted Date: 2020-09-16

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 2

Registration Number: NCT03116971

Locations: 🇪🇸
Research site 4, Madrid, Spain
🇧🇬
Reasearch site 5, Sofia, Bulgaria
🇧🇬
Research site 6, Sofia, Bulgaria

and more 4 locations

Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN

Phase 2

Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Lobaplatin
Drug: Cisplatin

First Posted Date: 2017-04-17

Last Posted Date: 2017-04-17

Lead Sponsor: Guiyang Medical University

Target Recruit Count: 144

Registration Number: NCT03117257

Locations: 🇨🇳
Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer

Phase 2

Completed

Conditions: HPV-Related Squamous Cell Carcinoma
HNSCC

Interventions: Drug: nab-paclitaxel
Procedure: Transoral robotic surgery (TORS)
Drug: Carboplatin
Drug: Cisplatin
Radiation: Adjuvant RT
Drug: Nivolumab
Drug: Hydroxyurea
Drug: 5-FU
Drug: Dexamethasone
Drug: Famotidine
Drug: Diphenhydramine
Drug: Paclitaxel
Radiation: Chemoradiotherapy

First Posted Date: 2017-04-11

Last Posted Date: 2024-10-11

Lead Sponsor: University of Chicago

Target Recruit Count: 76

Registration Number: NCT03107182

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Cisplatin
Drug: Gemcitabine
Drug: Anetumab ravtansine (BAY94-9343)

First Posted Date: 2017-04-05

Last Posted Date: 2022-06-30

Lead Sponsor: Bayer

Target Recruit Count: 173

Registration Number: NCT03102320

Locations: 🇧🇪
UZ Antwerpen, Edegem, Belgium
🇧🇪
CHU de Liège, Liege, Belgium
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

and more 69 locations

Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer

Phase 2

Completed

Conditions: Biliary Tract Neoplasms

Interventions: Drug: Gemcitabine
Drug: Ipilimumab
Drug: Cisplatin
Drug: Nivolumab

First Posted Date: 2017-04-05

Last Posted Date: 2022-10-28

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 75

Registration Number: NCT03101566

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 4 locations

Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

Phase 4

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Paclitaxel
Drug: Cisplatin
Drug: Vinblastine Sulfate
Drug: Carboplatin
Radiation: three dimensional conformal radiotherapy

First Posted Date: 2017-03-28

Last Posted Date: 2019-03-08

Lead Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Target Recruit Count: 60

Registration Number: NCT03092986

Locations: 🇧🇩
Department of Oncology,Bangabandhu Sheikh Mujib Medical university, Dhaka, Bangladesh

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy